Boston Scientific Corporation Share Price
Stocks
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Market Closed -
NYSE
21:00:02 15/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 43.87 USD | -2.62% |
|
-2.47% | -53.99% |
| Market Cap | 63.58B 55.07B 52.08B 47.15B 88.48B 6,099B 89.15B 621B 239B 3,092B 239B 234B 9,862B | P/E 2026 * |
16.6x | P/E 2027 * | 17.3x |
|---|---|---|---|---|---|
| Enterprise Value | 72.3B 62.63B 59.22B 53.62B 101B 6,936B 101B 707B 272B 3,517B 272B 266B 11,216B | EV / Sales 2026 * |
3.39x | EV / Sales 2027 * | 3.1x |
| Free-Float |
82.47% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| BSX | Delayed | |
CBOE
| BSX | Real-time | |
|
Wiener Boerse
| BSXC | End-of-day quote | |
|
Mexican S.E.
| BSX * | End-of-day quote | |
|
Tradegate
| BSX | Real-time | |
|
CBOE
| Real-time | ||
|
London S.E.
| 0HOY | Delayed | |
|
Swiss Exchange
| BSX | Delayed | |
|
Boerse Muenchen
| BSX | Real-time | |
|
Borsa Italiana
| 1BSX | End-of-day quote | |
|
Deutsche Boerse AG
| BSX | Delayed | |
|
Börse Stuttgart
| BSX | Delayed | |
|
Xetra
| BSX | Delayed | |
|
Swiss Exchange
| BSX | Delayed | |
|
CBOE
| 0HOY | Real-time |
Last Transcript: Boston Scientific Corporation
| 1 day | -2.62% | ||
| 1 week | -2.47% | ||
| Current month | -9.17% | ||
| 1 month | -15.36% | ||
| 3 months | -6.18% | ||
| 6 months | -36.54% | ||
| Current year | -53.99% |
| 1 week | 42.78 |  | 45.15 |
| 1 month | 42.78 | | 52.56 |
| Current year | 42.2 | | 100.9 |
| 1 year | 42.2 | | 105.65 |
| 3 years | 42.2 | | 109.5 |
| 5 years | 34.98 | | 109.5 |
| 10 years | 19.67 | | 109.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Mahoney
CEO | Chief Executive Officer | 61 | 31/10/2011 |
Jonathan Monson
DFI | Director of Finance/CFO | 52 | 29/06/2025 |
Kenneth Stein
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Mahoney
CHM | Chairman | 61 | 02/05/2016 |
Edward Ludwig
BRD | Director/Board Member | 74 | 28/02/2014 |
Ellen Zane
BRD | Director/Board Member | 74 | 14/04/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 25/08/26 | Buy | Director | 2,040 | 0.0001% | ||
| 11/08/26 | Other | Controller/Auditor | 2,930 | 0.0002% | ||
| 10/08/26 | Other | Chief Financial Officer | 9,908 | 0.0007% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.62% | -2.47% | -56.07% | -17.07% | 63.58B | |
| +4.53% | +6.36% | +35.18% | +24.41% | 237B | |
| +3.01% | +2.01% | +11.04% | -17.98% | 147B | |
| -0.21% | +7.71% | -13.09% | +27.62% | 133B | |
| -0.77% | -0.31% | -19.02% | -14.80% | 49.95B | |
| +0.26% | -1.13% | +12.74% | +17.13% | 49.42B | |
| +2.36% | +2.33% | +19.61% | +29.64% | 42.37B | |
| +1.73% | +3.52% | +39.48% | +51.23% | 40.98B | |
| +2.89% | +3.80% | -15.40% | +57.81% | 32.82B | |
| +6.76% | +5.32% | +120.26% | +52.10% | 33.57B | |
| Average | +1.63% | +0.14% | +13.47% | +21.01% | 83.03B | |
| Weighted average by Cap. | +1.89% | +2.15% | +12.43% | +15.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 21.32B 18.47B 17.47B 15.81B 29.68B 2,046B 29.9B 208B 80.19B 1,037B 80.1B 78.32B 3,308B | 22.3B 19.32B 18.27B 16.54B 31.04B 2,139B 31.27B 218B 83.87B 1,085B 83.77B 81.92B 3,459B |
| Net income | 3.8B 3.29B 3.11B 2.81B 5.28B 364B 5.32B 37.11B 14.28B 185B 14.26B 13.94B 589B | 3.68B 3.19B 3.01B 2.73B 5.12B 353B 5.16B 35.98B 13.84B 179B 13.83B 13.52B 571B |
| Net Debt | 8.73B 7.56B 7.15B 6.47B 12.15B 837B 12.24B 85.3B 32.82B 424B 32.78B 32.05B 1,354B | 5.47B 4.74B 4.48B 4.06B 7.61B 525B 7.67B 53.48B 20.58B 266B 20.55B 20.1B 849B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/09/26 | US$43.87 | -2.62% | 16,015,363 |
| 14/09/26 | US$45.05 | +4.82% | 20,521,670 |
| 11/09/26 | US$42.98 | -0.28% | 26,986,789 |
| 10/09/26 | US$43.10 | -4.14% | 22,690,902 |
| 09/09/26 | US$44.96 | -0.04% | 17,979,923 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSX Stock
Select your edition
All financial news and data tailored to specific country editions
